New

LipoSeuticals

The AI engine Fit Assessment

Beta

The company provides pharma tech solutions via a proprietary sugar-lipid-polymer reformulation platform for sterile injectable drugs, with a focus on research and development, a robust pipeline, and partnerships in anesthesiology, oncology, and infectious disease.

Blurb

Specialty pharmaceutical company.

HQ Location

South Brunswick Township (United States)

Founded

2012

Employees

11 - 50

Total funding raised

Not available

Funding Status

Series A, June 29, 2017

Developer of sterile injectable drugs designed to treat anesthesiology, oncology, and infectious diseases. The company's drugs specialize in non-water-soluble that is based on a patented, non-toxic, drug reformulation technology platform, which utilizes pure sugar-lipid polymers that can solubilize compounds and disperse them, enabling healthcare practitioners to reduce drug wastage through vial reuse and enhance stability, reduce costs via extended shelf-life and eliminate antibiotic resistance and toxic recipients.